Bayer Animal Health reported today that it is expanding its international companion animal portfolio with two new European Commission-approved products: Veraflox (pradofloxacin) and Procox (emodepside and toltrazuril).
The company describes Veraflox as the first next-generation veterinary fluoroquinolone antibiotic for the treatment of bacterial infection in dogs and cats.
The European Commission granted approval for the treatment of the following infections caused by specified and susceptible pathogens: wound infections, superficial and deep pyoderma, acute urinary tract infections and as adjunctive treatment for severe gingival and periodontal tissue infections in dogs; and against wound infections, abscesses and acute upper respiratory tract infections in cats.
The product is available in flavored tablets for dogs and cats as well as an oral suspension for cats.
Veraflox is approved in 30 European countries and will be launched in the first markets “shortly,” according to Bayer Animal Health.
Procox is the first and only licensed combination treatment for roundworm and coccidia gastrointestinal parasitic infections in dogs, according to the company. This includes puppies of at least two weeks of age and weighing at least 0.9 pounds.
The product is available as an oral suspension.
Procox is approved in 27 European countries and the first launches are planned for the third quarter of this year.